Dupilumab (and the newer JAK inhibitors: upadacitinib, abrocitinib, baricitinib) are systemic treatments for moderate-to-severe atopic dermatitis that hasn't responded adequately to topical care. They target specific parts of the Th2 immune pathway that drive eczema and work well: roughly three-quarters of people on dupilumab achieve a 75% improvement in severity scores within sixteen weeks. They're appropriate when topical steroids, emollients, and systematic trigger identification haven't produced adequate control after a genuine trial, and when the condition is significantly affecting sleep, work, or quality of life. They're not appropriate as a first-line shortcut past proper barrier and trigger work.
What these drugs actually do
Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, which is shared by IL-4 and IL-13, the two cytokines doing most of the work in atopic dermatitis. By blocking this signalling, dupilumab reduces the Th2-polarised inflammation that drives barrier dysfunction, itch, and the chronic flare-remit cycle.
JAK inhibitors (upadacitinib, abrocitinib, baricitinib) block Janus kinases, which are intracellular signalling molecules used by many immune cytokines. They're broader in action and taken as tablets rather than injections. They work faster than dupilumab on itch (often within days) and achieve comparable or slightly higher clearance rates, but they carry a wider range of potential side effects and are prescribed with more caution.
Both classes represent a genuine change in outcomes. Before them, the only systemic options were oral immunosuppressants (ciclosporin, methotrexate, azathioprine), which work but carry significant long-term organ-toxicity risks.
Who's eligible
In the UK, NICE guidance currently approves dupilumab and the JAK inhibitors for adults (and for dupilumab, children above age 6) with moderate-to-severe atopic dermatitis that hasn't responded adequately to at least one systemic immunosuppressant, or where systemic immunosuppressants aren't suitable. "Moderate-to-severe" is assessed using validated scoring tools (EASI, IGA), not self-report.
Practically this means a pathway: GP referral to a dermatology specialist, specialist assessment including severity scoring, a documented trial of optimised topical therapy, usually a trial of ciclosporin first (unless contraindicated), and then referral for biologic or JAK-inhibitor therapy if the earlier steps haven't delivered control. The pathway takes months, typically, not weeks.
When it's the right answer
Biologic therapy makes sense when: you've done an optimised topical regimen (emollient three times a day, mid-potency topical steroid applied correctly during flares, avoidance of identified triggers) for at least three months and the disease is still severe; the condition is affecting sleep most nights, or work, or mood, or causing recurrent infections; and the trajectory is not improving despite a consistent effort. See the separate note on why standard treatments so often fail for what "optimised" actually means in practice, because the most common reason people are "treatment-resistant" is that the topical regimen hasn't been applied the way it needs to be.
When it's the wrong answer
Biologics are the wrong answer when they're being reached for instead of, rather than after, a proper barrier and trigger identification effort. A patient who hasn't tried a structured 45-day protocol of barrier repair plus systematic trigger identification is one who may have much of their inflammation being actively driven by modifiable exposures: dust mites, hard water, specific foods, detergents, stress. Starting a biologic without addressing those leaves you dependent on the drug to suppress inflammation that's being actively generated.
This isn't anti-biologic. It's an argument that biologics work best on the subset of inflammation that can't be addressed by changing inputs, which is real but is usually smaller than people assume until they've tried.
Side effects and practicalities
Dupilumab's common side effects are injection-site reactions (minor), conjunctivitis (~10% of patients, sometimes significant), and occasional facial redness that looks like new eczema but isn't. It's given as a subcutaneous injection every two weeks, usually self-administered.
JAK inhibitor side effects are broader: increased infection risk (particularly herpes zoster), laboratory abnormalities (lipid changes, blood cell counts), and a need for regular monitoring. There are FDA-mandated warnings about cardiovascular events and malignancy risk in an older patient population on related drugs; the relevance to younger atopic dermatitis patients is uncertain but means the drugs are prescribed with more caution in people over fifty or with cardiovascular risk factors.
Cost is relevant: in the UK these are prescribed through NHS dermatology services where the patient pays only the prescription charge; privately the retail cost of dupilumab alone is several thousand pounds a year.
The realistic sequence
For someone with persistent eczema who is considering next steps, a reasonable sequence is: (1) a full 45-day structured protocol of barrier repair, elimination diet if diet is suspected, and systematic trigger identification; (2) if not adequately controlled, GP review and referral to dermatology; (3) specialist-guided optimisation of topical therapy and short courses of oral therapy; (4) if disease is still moderate-to-severe, assessment for dupilumab or JAK-inhibitor therapy.
Biologic therapy is a good answer in the right place in that sequence. It's the fourth step, not the first.
Reviewed by the xmahub protocol team. Based on peer-reviewed dermatology literature.